Jubilant Pharmova Revenue Rises 21% as Q2 Profit Falls 74%
Key highlights
- Jubilant Pharmova reported Q2 FY27 revenue of ₹2,370 crore, up 20.5% year-on-year.
- Reported Q2 FY27 profit after tax fell 74.1% year-on-year to ₹31 crore.
- EBITDA excluding other income was ₹241 crore, with a 10.1% margin versus 17.1% a year earlier.
- The Montreal facility reported a Q2 FY27 loss of more than ₹80 crore.
powered by IRIS

Jubilant Pharmova Limited reported Q2 FY27 revenue of ₹2,370 crore, up 21% year-on-year, while reported profit after tax fell 74.1% to ₹31 crore. Broad-based growth across businesses supported sales, but unavailable high-margin SPECT products and higher costs at its Montreal facility reduced profitability.
Know Jubilant Pharmova inside out
Results, valuation, peers and who's buying, in one view.
What were Jubilant Pharmova's Q2 FY27 financial results?
Jubilant Pharmova posted consolidated revenue from operations of ₹2,370 crore for the quarter ended September 30, 2026, compared with growth of 20.5% reported in its filed results. Revenue was also 6.3% higher sequentially. The company said growth was recorded across CDMO sterile injectables, allergy, radiopharma and generics.
Reported EBITDA stood at ₹255 crore and reported profit after tax was ₹31 crore. The filed quarterly table showed EBITDA excluding other income of ₹241 crore, down 28.3% year-on-year, with a 10.1% margin compared with 17.1% a year earlier. The company reported an operating margin of about 10.2%, based on rounding. Earnings per share fell 74.0% year-on-year to ₹1.97.
For the first half of FY27, revenue increased 19% year-on-year to ₹4,599 crore. H1 EBITDA was ₹523 crore and profit after tax was ₹87 crore. The reported figures reflect a gap between strong revenue expansion and lower operating profitability during the period.
Why did Jubilant Pharmova's margins decline despite higher revenue?
Jubilant Pharmova said the absence of high-margin SPECT radiopharmaceutical products was a principal reason for the year-on-year margin decline. It also cited negligible third-party revenue from the Montreal facility, higher operating expenses and incremental remediation costs at that location.
The Montreal CDMO facility recorded a loss of more than ₹80 crore in Q2 FY27, according to management. Its H1 loss was about ₹157 crore. The company also indicated that cumulative losses since the Official Action Indicated, or OAI, issues began were around ₹357 crore, including approximately ₹200 crore of earlier losses.
Lower operating profitability and increased depreciation also reduced reported profit. Profit before tax fell 67.58% year-on-year to ₹61.7 crore from ₹190.3 crore. These disclosures show that the pressure was concentrated in costs and product mix rather than the company’s consolidated revenue base.
Which businesses supported Jubilant Pharmova's revenue growth?
Jubilant Pharmova attributed its quarterly sales growth to contributions across its operating businesses, with CDMO sterile injectables benefiting particularly from technology-transfer revenue related to its new and third lines. Management also identified allergy, radiopharma and generics as contributors to the consolidated revenue increase.
The generics business reported revenue of ₹274 crore, up 64% year-on-year, and EBITDA of ₹20 crore, up 46%. The company linked this performance to contributions from multiple new product launches during FY27. These figures made generics one of the faster-growing businesses disclosed for the quarter.
Management said higher production volumes were improving gross margins across the portfolio. However, this benefit was not sufficient to offset the quarter’s Montreal remediation spending and the missing contribution from higher-margin SPECT radiopharmaceutical products.
Got a follow-up? Ask IRIS
What is Jubilant Pharmova's outlook for Montreal and capacity additions?
Jubilant Pharmova expects commercial production at Montreal to begin in the second half of FY27, with operations expected to normalise by FY28 or FY29. The company described stabilisation in Montreal SPECT supplies as a factor behind revenue growth, while also acknowledging the site’s continuing cost burden in the reported quarter.
For H2 FY27, management expects revenue momentum to continue and expects margins to improve sequentially, with average H2 margins in the mid-teens. This is management guidance, not a reported result, and it depends on the operating recovery and product availability cited during the earnings call.
The company also outlined capacity expansion plans. Line 4 and new PET manufacturing sites are planned to come on stream in FY28. These additions form part of the company’s stated plan to raise production capacity in radiopharma and related operations.
How do the results affect investors and the pharmaceutical business?
For investors, the quarter showed that Jubilant Pharmova is growing sales at a double-digit rate while facing a significant earnings drag from Montreal and the radiopharma product mix. Revenue growth was broad-based, but the 74.1% fall in profit after tax and the EBITDA-margin decline show that higher sales did not translate into comparable profit growth.
The results also underline the importance of the Montreal recovery for the company’s financial performance. Management’s H2 margin guidance is tied to expected operational improvement, while the disclosed quarterly loss of more than ₹80 crore demonstrates the scale of the current burden. The planned FY28 capacity additions provide a longer-term operational milestone, but no financial contribution from them was quantified in the disclosed material.
Conclusion
Jubilant Pharmova delivered ₹2,370 crore of Q2 FY27 revenue, supported by growth across multiple businesses and especially strong generics sales. Yet, the loss at Montreal, remediation expenses and the unavailability of high-margin SPECT products reduced EBITDA margins and brought profit after tax down to ₹31 crore.
The next disclosed checkpoints are the start of commercial production at Montreal in H2 FY27, management’s target for mid-teen average H2 margins and the planned commissioning of Line 4 and new PET manufacturing sites in FY28. Progress on these operating milestones will be relevant to the company’s margin recovery plan.


